Gynecologic Oncology | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics: Gynecologic Oncology   Introduction (0:00) Ovarian Cancer    PARP inhibitors as primary maintenance (8:11) PARP inhibitors for recurrent and metastatic disease (19:04) Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39) Endometrial Cancer   Immunotherapy for metastatic disease (43:49) Selinexor as maintenance therapy (51:33) Other novel agents (56:52) Cervical Cancer   Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00) CME information and select publications

Om Podcasten

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.